A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

To join this study, you would need to have a confirmed diagnosis of urothelial cancer that is either advanced in a local area or has spread to other parts of the body. This cancer could be in your bladder, kidney, ureter, or urethra. A key requirement is that your cancer has not responded to previous treatments that work by boosting your immune system (called PD-1/L1 inhibitors).

You would also need to provide a sample of your cancer tissue. This can be a sample that was taken previously and saved, or it might involve taking a new small tissue sample (biopsy) from one of your cancer sites. This helps researchers understand more about your cancer and how it might respond to the new treatments.

There are also some reasons why you might not be able to join. For example, if you have another type of cancer that is active or has needed treatment in the last three years. Also, you couldn't have had other cancer treatments, including other experimental drugs, within the last four weeks before starting the study.

If you decide to take part in this study, you will receive one or more investigational medicines. These are drugs that are still being tested to see if they are safe and effective. You'll have regular visits to the clinic so the study doctors can carefully monitor your health and how the treatment is affecting you. These visits will involve various tests, such as blood tests, scans, and physical examinations, to check the cancer and your overall well-being. The treatment schedule and frequency of visits will depend on which study medicine you receive. You will continue to be monitored throughout the treatment period and for a follow-up period afterwards. The total time you'd be involved in the study would vary depending on your medical response and the specific treatment plan, but it could potentially last for several months or longer.